Excellent post as always Moz, keeping me excited for both the potential of MPS/OA and the other diseases iPPS may be a game changer for.
Alzheimer's, Parkinson's, and Huntington's have a lot in commom, and cell death and inflammation play a big part in each.
Once we finally have revenue and some runs on the board, it's amazing to think how many different diseases the company can begin performing preclinical work on.
As most of this work is performed by different CRO's, the only limits will be R&D funds and the imagination of the company.
Seriously a lot of potential for iPPS to help a lot of people. Something like a third of chronic health conditions in Australia are arthritic or back pain if my memory from the 2021 numbers is correct.
Anti inflammatory and prevents cell death would be a wicked combo for a lot of these.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)